Laboratory response to paradigm change in hemophilia treatment.

Shafaati Lambert, Marjan; Bruzelius, Maria; Mahmoud Hourani Soutari, Nida; Ranta, Susanna; Antovic, Jovan P

Shafaati Lambert, Marjan; Bruzelius, Maria; Mahmoud Hourani Soutari, Nida; Ranta, Susanna; Antovic, Jovan P.

Afiliación

Shafaati Lambert M; Coagulation & Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Bruzelius M; Coagulation, Clinical Chemistry, Karolinska University Laboratory, Medical Diagnostics Karolinska, Karolinska University Hospital, Stockholm, Sweden.
Mahmoud Hourani Soutari N; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Ranta S; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Antovic JP; Coagulation & Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Clin Chem Lab Med ; 61(12): e248-e250, 2023 11 27.

Article en En | MEDLINE | ID: mdl-37319338

Asunto(s)

Hemofilia A; Humanos; Hemofilia A/diagnóstico; Hemofilia A/terapia; Factor VIII/uso terapéutico; Tiempo de Tromboplastina Parcial; Laboratorios

Palabras clave

FVIII concentrate; FVIII:C CSA; emicizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hemofilia A Límite: Humans Idioma: En Revista: Clin Chem Lab Med Asunto de la revista: QUIMICA CLINICA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2023 Tipo del documento: Article País de afiliación: Suecia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google